A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/28/2006	US20060293321 2-Heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer
12/28/2006	US20060293320 Heteroaryl derivatives for treating viruses
12/28/2006	US20060293319 Oxindole derivatives
12/28/2006	US20060293318 Stereospecifically substituted benzo[1,3]dioxolyl derivatives
12/28/2006	US20060293317 Use of non-steroidal progesterone receptor modulators
12/28/2006	US20060293316 such as Cis-6-Phenyl-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo [2,1a]isoquinoline, used as histamine H3 receptor and serotonin transporter modulators useful in the treatment of depression
12/28/2006	US20060293315 Intermediates of novel heterocyclic compounds having antibacterial activity and process for their preparation
12/28/2006	US20060293314 4- Piridinylmethylsulphonamide derivatives as fungicidal plant protein agents
12/28/2006	US20060293313 Indole-3-alkyl-N-piperazine ring substituted with quinoline ring or derivatives; shows high affinity for both the dopamine D2 receptor and the serotonin reuptake site, useful for treating central nervous system disorders, such as anxiety disorders, depression, Parkinson's disease, and schizophrenia
12/28/2006	US20060293312 Method of improved diuresis in individuals with impaired renal function
12/28/2006	US20060293311 Compositions and methods for inhibition of the jak pathway
12/28/2006	US20060293310 Derivatives of 1-piperazine-and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme
12/28/2006	US20060293309 Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
12/28/2006	US20060293308 Pyridyl derivatives and their use as therapeutic agents
12/28/2006	US20060293307 Oxazolidinone derivatives as antimicrobials
12/28/2006	US20060293306 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons
12/28/2006	US20060293305 5-(2-amino-5-oxo-1,5-dihydro-imidazol-4-ylidene)-3,4,5,10-tetrahydro-2H-azepino[3,4-b]indol-1-one, used for treating inflammatory disorders selected from arthritis, inflammatory bowel disease, asthma, dermatitis and transplant rejection; inhibiting production of a cytokine in cells; enzyme inhibitors
12/28/2006	US20060293304 Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
12/28/2006	US20060293303 e.g. 2-(4-Fluorophenyl)-7-(1-methylpiperidin-4-yl)-3-(2-methylpyrimidin-4-yl)imidazo[1,2-a]-pyridine; protozoal diseases (toxoplasmosis, malaria, African typanosomiasis, Chagas disease, and opportunistic infections) in mammals and birds; controlling coccidiosis in poultry
12/28/2006	US20060293302 For therapy of acute inflammatory diseases: Septic shock, sepsis, SIRS, hemorrhagic shock, shock states induced by cytokine therapy (IL-2, TNF), organ transplantation and transplant rejection, head trauma, acute lung injury, ARDS, inflammatory skin conditions such as sunburn, inflammatory eye conditions
12/28/2006	US20060293301 Use of compounds that inhibit serotonin reuptake and are antagonists of the 5HT1A receptor; 2-[3-(5-fluoro-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline for example; depression, anxiety, premenstrual syndrome, attention deficit disorder, eating disorders
12/28/2006	US20060293300 New substituted thiophene carboxamides, process for their preparation and their use as medicaments
12/28/2006	US20060293299 3-((1S)-1-{1-[(S)-(3-cyanophenyl)(4-cyanophenyl)methyl]azetidin-3-yl}-2-fluoro-2-methylpropyl)-5-fluorobenzonitrile and its salts; antagonists and inverse agonists of the Cannabinoid-1 receptor
12/28/2006	US20060293298 Compounds
12/28/2006	US20060293297 Cyanofluoropyrrolidine derviative
12/28/2006	US20060293296 Process for the preparation of cefpodoxime procetil
12/28/2006	US20060293295 Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
12/28/2006	US20060293294 Method for treatment or prevention of androgen deficiency
12/28/2006	US20060293293 Salmeterol and ciclesonide combination
12/28/2006	US20060293292 METHODS OF USING ACYL HYDRAZONES AS sEH INHIBITORS
12/28/2006	US20060293291 bone formation is desired, such as osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus; exhibit pronounced activity in arresting the proliferation of undifferentiated cells; 2-[(3'-methoxymethoxy)propylidene]-19-nor-1 alpha ,25-(OH)2,D3
12/28/2006	US20060293290 oral dosage form antiacne agnt containing minocycline antibiotic; lactose monohydrate a fast dissolving carrier; hydroxypropylmethyl cellulose a slow dissolving carrier; fewer side effects
12/28/2006	US20060293289 Moderator of neurotransmitters releasing; analgesics ; central nervous system disorders; using N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine
12/28/2006	US20060293288 Use of resolvins to treat gastrointestinal diseases
12/28/2006	US20060293286 Resistant-repellent retroviral protease inhibitors
12/28/2006	US20060293285 Aryl Phosphate Derivatives of d4T
12/28/2006	US20060293284 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
12/28/2006	US20060293283 Prodrugs of A2B adenosine receptor antagonists
12/28/2006	US20060293282 Substituted aminoalkanephosphonic acids
12/28/2006	US20060293281 N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
12/28/2006	US20060293280 1,3-Oxathiolane-2-thione compounds
12/28/2006	US20060293279 Administration of enoxaparin sodium to patients with severe renal impairment
12/28/2006	US20060293278 Novel therapeutic uses of glucan
12/28/2006	US20060293277 Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making for making them
12/28/2006	US20060293276 Use of lipid conjugates in the treatment of disease
12/28/2006	US20060293275 Hgf production accelerator containing heparin-like oligosaccharide
12/28/2006	US20060293274 Cancer therapy
12/28/2006	US20060293273 Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient
12/28/2006	US20060293266 Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
12/28/2006	US20060293265 Methods involving aldose reductase inhibitors
12/28/2006	US20060293264 STAT3 decoy oligonucleotides and uses therefor
12/28/2006	US20060293263 Preparation for preventing contact of pathogenic matter with living organism
12/28/2006	US20060293261 Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
12/28/2006	US20060293259 Compositions and methods of use of derivatized flavanols
12/28/2006	US20060293258 Method and composition to treat skin ulcers
12/28/2006	US20060293257 Topically applying flavonoids
12/28/2006	US20060293256 Remedy or preventive for kidney disease and method of diagnosing kidney disease
12/28/2006	US20060293255 Method for regulating nutrient absorption with ginsenosides
12/28/2006	US20060293254 Podophyllotoxin
12/28/2006	US20060293253 Indole compounds useful for the treatment of cancer
12/28/2006	US20060293252 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics
12/28/2006	US20060293251 Substituted indazole-O-glucosides
12/28/2006	US20060293250 Crystalline sugar compositions and method of making
12/28/2006	US20060293249 Porphyrin derivatives
12/28/2006	US20060293248 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
12/28/2006	US20060293242 Transporting of taxoid derivatives through the blood brain barrier
12/28/2006	US20060293241 Pharmaceutical composition comprising a factor VII polypeptide and epsilon-aminocaproic acid
12/28/2006	US20060293239 Treatment and Diagnosis of Insulin-Resistant States
12/28/2006	US20060293236 Injectable Osteogenic Formula and Method of Using Same
12/28/2006	US20060293229 Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
12/28/2006	US20060293222 inhibitor of a phosphodiesterase 4 isoform is selected from cis-4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl) cyclohexane-1-carboxylic acid; 2-(4-(6,7-diethoxy-2,3bis(hydroxymethyl)napthalen-1-yl)pyridin-2-yl)-)-4-(3-pyridyl)pthalazin-1 (2H)-one hydrochloride; roflumilast, piclamilast, arofylline
12/28/2006	US20060293221 Mucosal repair by TFF2 peptides
12/28/2006	US20060293218 Salicylate therapeutic compound and process for controlled delivery thereof
12/28/2006	US20060293217 Pharmaceutical formulations for sustained release
12/28/2006	US20060293216 Pharmaceutical compositions comprising an active agent and chitosan for sustained drug release or mucoadhesion
12/28/2006	US20060293206 Disinfection agent for suction systems used in the field of medicine or dentistry
12/28/2006	US20060292689 CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
12/28/2006	US20060292670 Nell peptide expression systems and bone formation activity of nell peptide
12/28/2006	US20060292633 Method for modulating process mediated by farnesoid activated receptors
12/28/2006	US20060292254 Orally and nasally administered appetite suppressant
12/28/2006	US20060292253 Active substance combination of licochalcone A and phenoxyethanol
12/28/2006	US20060292251 Method for enhancing nutrient absorption with astragalosides
12/28/2006	US20060292250 Supplement composition and method of use for enhancement of anti-inflammation process
12/28/2006	US20060292247 Neutralizing agent for toxin of Clostridium microorganisms
12/28/2006	US20060292244 Use of pvp-iodine liposomes for treatment of acne
12/28/2006	US20060292226 Fatty emulsion injection of seal oil, method for preparation and the use in manufacturing intravenous injection
12/28/2006	US20060292225 Water soluble analgesic formulations and methods for production
12/28/2006	US20060292223 Gel compositions for topical administration
12/28/2006	US20060292221 Multilayer tablet; core containing drug with erodible filler and overcoating
12/28/2006	US20060292220 Compositions and methods for nutrition supplementation
12/28/2006	US20060292219 Making a tablet by combining a drug such as fentanyl with an effervescent agent used as penetration enhancer to influence the permeability of the medicament in the oral cavity; compressing to form tablet
12/28/2006	US20060292218 A cytocidyl mixture of alpha-ketoglutaric acid and salts, N-acetyl-seleno-L-methionine, N-acetyl-L-methionine, and 5-hydroxymethylfurfural that is capable of forming azomethine; angiogenesis inhibition; cancerous tumors of the breast, uterus, esophagus, bladder, lung
12/28/2006	US20060292217 Nutritional supplement and soft gelatin capsule delivery system
12/28/2006	US20060292216 Enteric delivery of (-)-hydroxycitric acid
12/28/2006	US20060292215 Abscisic acid against cancer
12/28/2006	US20060292213 Enoximone formulations and their use in the treatment of PDE-III mediated diseases
12/28/2006	US20060292210 Percutaneous absorption-type pharmaceutical preparation
12/28/2006	US20060292207 Chitosan based dressing
12/28/2006	US20060292204 5,7,3',4'-Tetrahydroxy-5'-C-geranylflavanone (isonymphaeol-B), isolated from an Okinawa propolis; microbiocide, antitumor agent, food, beverage and cosmetic preservative; antioxidant food supplement
12/28/2006	US20060292203 Methods and compositions for the treatment of ocular disorders

1 ... 3946 3947 3948 3949 3950 3951 3952 3953 3954 3955 3956 3957 3958 3959 3960 3961 3962 3963 3964 3965 3966 ... 7860